Italian drugmaker Recordati (RECI: MI) has reported strong net revenues of 551 million euros ($600 million) in the first quarter of 2023, up 31.5%.
With solid growth in its portfolio of primary care and specialty care products, the Milanese firm upped its 2023 financial guidance, forecasting revenues of between 2.05 and 2.09 billion euros. Recordati shares were up 3.8% at 44.79 euros by late afternoon.
The new net profit guidance is for between 490 million and 500 million euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze